Development, Commercialization and Supply Agreements - Additional Information (Detail)	1 Months Ended													3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2026 USD ($)	Feb. 28, 2025 USD ($)	Oct. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)	Oct. 31, 2023 USD ($)	Feb. 28, 2023 USD ($)	Jan. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) Country	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2018 USD ($)
License And Collaboration Agreements [Line Items]
Licenses revenue														$ 42,211,000	$ 72,741,000	$ 87,344,000	$ 114,757,000
Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue														39,077,000	46,617,000	82,403,000	87,652,000
Mochida Pharmaceutical Co., Ltd. \| In-licenses
License And Collaboration Agreements [Line Items]
Milestones payment	$ 1,000,000	$ 1,000,000
Mochida Pharmaceutical Co., Ltd. \| In-licenses \| Research and Development Expense
License And Collaboration Agreements [Line Items]
Up-front payment																			$ 2,700,000
Edding \| Achievement of REDUCE-IT Trial \| VASCEPA
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received				$ 15,000,000
Edding \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received													$ 15,000,000
Sales-based milestone event payment														120,000,000		120,000,000
Edding \| Out-licenses \| Royalties
License And Collaboration Agreements [Line Items]
Licenses revenue														700,000	600,000	1,200,000	900,000
Edding \| Out-licenses \| Maximum
License And Collaboration Agreements [Line Items]
Sales-based milestone event payment														50,000,000		50,000,000
Edding \| Out-licenses \| Minimum
License And Collaboration Agreements [Line Items]
Sales-based milestone event payment														5,000,000		5,000,000
Edding \| Out-licenses \| Clinical Trial Application
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received												$ 1,000,000
Edding \| Out-licenses \| Achievement of REDUCE-IT Trial
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received					$ 3,000,000
Edding \| Out-licenses \| MARINE \| VASCEPA
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received											$ 5,000,000
Biologix FZCo \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue														700,000	2,700,000	1,200,000	2,700,000
HLS \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received										$ 5,000,000
Non-refundable milestone payment received							$ 3,800,000
HLS \| Out-licenses \| Health Canada
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received								$ 2,500,000	$ 2,500,000
HLS \| Out-licenses \| Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue														400,000	0	400,000	0
HLS \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue														700,000	0	700,000	0
HLS \| Out-licenses \| Royalties
License And Collaboration Agreements [Line Items]
Licenses revenue														700,000	500,000	1,400,000	1,200,000
HLS \| Out-licenses \| Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone										$ 47,500,000
CSL Seqirus \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received						$ 500,000
Non-refundable milestone payment received			$ 1,200,000
Upfront payment receivable						500,000
Event-related milestone payments receivable						6,000,000
Additional product-related milestone payments receivable						$ 4,000,000
CSL Seqirus \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue														0	800,000	$ 2,000,000	800,000
Recordati Industria Chimica e Farmaceutica S.p.A.
License And Collaboration Agreements [Line Items]
Number of countries \| Country																59
Recordati Industria Chimica e Farmaceutica S.p.A. \| Out-licenses
License And Collaboration Agreements [Line Items]
Up-front payment																		$ 25,000,000
Recordati Industria Chimica e Farmaceutica S.p.A. \| Out-licenses \| Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue														0	25,000,000	$ 0	25,000,000
Recordati Industria Chimica e Farmaceutica S.p.A. \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue														5,400,000	0	8,400,000	0
Recordati Industria Chimica e Farmaceutica S.p.A. \| Out-licenses \| Royalties
License And Collaboration Agreements [Line Items]
Licenses revenue														$ 1,400,000	$ 0	$ 2,000,000	$ 0
Recordati Industria Chimica e Farmaceutica S.p.A. \| Out-licenses \| Maximum
License And Collaboration Agreements [Line Items]
Milestones payment																		$ 150,000,000